These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33939937)

  • 1. "The Doctor Says You Cannot Have [Buprenorphine]" Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine.
    Hayes BT; Jakubowski A; Fitzsimmons C; Garcia B; Ramirez F; Fox AD
    Subst Use Misuse; 2021; 56(8):1137-1143. PubMed ID: 33939937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
    Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
    Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis.
    Daniulaityte R; Nahhas RW; Silverstein S; Martins S; Zaragoza A; Moeller A; Carlson RG
    Drug Alcohol Depend; 2019 Nov; 204():107574. PubMed ID: 31568934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis.
    Daniulaityte R; Nahhas RW; Silverstein S; Martins S; Carlson RG
    J Subst Use Addict Treat; 2023 Apr; 147():208973. PubMed ID: 36804351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Prescribed Substance Use during the First Month of Treatment by People Receiving Depot Buprenorphine for Opioid Use Disorder.
    Parkin S; Neale J; Strang J
    Subst Use Misuse; 2023; 58(13):1696-1706. PubMed ID: 37571999
    [No Abstract]   [Full Text] [Related]  

  • 6. "They're making it so hard for people to get help:" Motivations for non-prescribed buprenorphine use in a time of treatment expansion.
    McLean K; Kavanaugh PR
    Int J Drug Policy; 2019 Sep; 71():118-124. PubMed ID: 31330267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder.
    Williams AR; Mauro CM; Feng T; Wilson A; Cruz A; Olfson M; Crystal S; Samples H; Chiodo L
    J Subst Abuse Treat; 2022 Aug; 139():108770. PubMed ID: 35337715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does incarceration influence patients' goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail.
    Vail W; Faro E; Watnick D; Giftos J; Fox AD
    Drug Alcohol Depend; 2021 May; 222():108529. PubMed ID: 33810909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
    Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
    J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City.
    Truong C; Krawczyk N; Dejman M; Marshall-Shah S; Tormohlen K; Agus D; Bass J
    Addict Behav; 2019 Jun; 93():14-19. PubMed ID: 30682677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
    Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
    J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.
    Clay S; Treloar C; Degenhardt L; Grebely J; Christmass M; Gough C; Hayllar J; McDonough M; Henderson C; Crawford S; Farrell M; Marshall A
    Int J Drug Policy; 2023 May; 115():104002. PubMed ID: 37003194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
    Johnson B; Monwell B; Capusan AJ
    Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How do patients feel during the first 72 h after initiating long-acting injectable buprenorphine? An embodied qualitative analysis.
    Neale J; Parkin S; Strang J
    Addiction; 2023 Jul; 118(7):1329-1339. PubMed ID: 36808168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs' perspectives of and experiences with the extramedical use and diversion of buprenorphine.
    Sud A; Salamanca-Buentello F; Buchman DZ; Sabioni P; Majid U
    J Subst Abuse Treat; 2022 Apr; 135():108651. PubMed ID: 34728134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 18. "I'm a Survivor": Perceptions of Chronic Disease and Survivorship Among Individuals in Long-Term Remission from Opioid Use Disorder.
    Pytell JD; Sklar MD; Carrese J; Rastegar DA; Gunn C; Chander G
    J Gen Intern Med; 2022 Feb; 37(3):593-600. PubMed ID: 34027611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "
    Checkley L; Steiger S; Knight KR
    Subst Abus; 2022; 43(1):767-773. PubMed ID: 35112998
    [No Abstract]   [Full Text] [Related]  

  • 20. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.